Universität zu Köln

Lang, Gabriele E., Stahl, Andreas ORCID: 0000-0002-8013-7597, Voegeler, Jessica, Quiering, Claudia, Zaremba, Laureen, Lorenz, Katrin, Spital, Georg and Liakopoulos, Sandra (2022). Observational outcomes in proliferative diabetic retinopathy patients following treatment with ranibizumab, panretinal laser photocoagulation or combination therapy - The non-interventional second year follow-up to the PRIDE study. Acta Ophthalmol., 100 (2). S. E578 - 10. HOBOKEN: WILEY. ISSN 1755-3768

Full text not available from this repository.

Abstract

Purpose Ranibizumab monotherapy showed stronger effects on area of retinal neovascularization (NV) reduction while offering better visual acuity (VA) results than panretinal laser photocoagulation (PRP) monotherapy during the first 12 months of the PRIDE study. The second year of PRIDE was an observational, non-interventional follow-up, performed to evaluate long-term anatomical and functional outcomes in proliferative diabetic retinopathy (PDR) patients under real-life conditions, prior to the approval of ranibizumab for PDR. Methods Seventy-three PDR patients (28 from the ranibizumab group; 20 from the PRP group; 25 from the combination group) were included in the observational follow-up phase and treated at the investigators discretion. Visual acuity (VA) measurements and retinal imaging were performed at Months 12, 18 and 24. Results Mean (+/- SD) NV area in the ranibizumab monotherapy and combination follow-up groups increased from 3.16 +/- 4.30 mm(2) and 1.13 +/- 2.78 mm(2) at Month 12 to 6.09 +/- 10.79 mm(2) and 2.14 +/- 4.41 mm(2) at Month 18 and 10.00 +/- 17.63 mm(2) and 3.26 +/- 7.05 mm(2) at Month 24, respectively. In the PRP follow-up group, NV area declined from 5.44 +/- 14.55 mm(2) at Month 12 to 1.22 +/- 1.67 mm(2) at Month 18, but increased again to 4.05 +/- 11.66 mm(2) at Month 24. During the observational phase, only 2 (6;8) patients in the ranibizumab (PRP;combination) follow-up group were treated with anti-VEGF medications, while 17 (6;10) patients received PRP laser therapy. Conclusion Discontinuation of ranibizumab treatment in PDR patients may result in an increase of NV area and VA loss. Tight monitoring of disease activity and continued treatment beyond the first year is needed to maintain disease control.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Lang, Gabriele E. UNSPECIFIED UNSPECIFIED UNSPECIFIED Stahl, Andreas UNSPECIFIED orcid.org/0000-0002-8013-7597 UNSPECIFIED Voegeler, Jessica UNSPECIFIED UNSPECIFIED UNSPECIFIED Quiering, Claudia UNSPECIFIED UNSPECIFIED UNSPECIFIED Zaremba, Laureen UNSPECIFIED UNSPECIFIED UNSPECIFIED Lorenz, Katrin UNSPECIFIED UNSPECIFIED UNSPECIFIED Spital, Georg UNSPECIFIED UNSPECIFIED UNSPECIFIED Liakopoulos, Sandra UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-597652
DOI:	10.1111/aos.14907
Journal or Publication Title:	Acta Ophthalmol.
Volume:	100
Number:	2
Page Range:	S. E578 - 10
Date:	2022
Publisher:	WILEY
Place of Publication:	HOBOKEN
ISSN:	1755-3768
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language Ophthalmology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/59765